{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:13:38Z","timestamp":1788484418169,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2022-01151"],"award-info":[{"award-number":["2022-01151"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2025-02853"],"award-info":[{"award-number":["2025-02853"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016669","name":"Sj\u00f6berg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["25 4398 Pj 01 H"],"award-info":[{"award-number":["25 4398 Pj 01 H"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["21-1790"],"award-info":[{"award-number":["21-1790"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["211749Pj"],"award-info":[{"award-number":["211749Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"publisher","award":["KAW 2023.0212"],"award-info":[{"award-number":["KAW 2023.0212"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218728","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:42:13Z","timestamp":1784734933000},"page":"218728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Vascular leakage in non-small cell lung cancer is associated with immune evasion and poor response to immunotherapy"],"prefix":"10.1016","volume":"658","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3572-9021","authenticated-orcid":false,"given":"Emmanuel","family":"Nwadozi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Strell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Nordling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Backman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Daller","family":"Cosmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Marwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Goldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5787-0072","authenticated-orcid":false,"given":"Johan","family":"Isaksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Botling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-138X","authenticated-orcid":false,"given":"Hans","family":"Brunnstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Lindskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Micke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Claesson-Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218728_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218728_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-1-4939-3801-8_6","article-title":"Measuring vascular permeability in vivo","volume":"1458","author":"Meijer","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218728_bib3","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1038\/s41596-020-0328-2","article-title":"In vivo compression and imaging in mouse brain to measure the effects of solid stress","volume":"15","author":"Nia","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2026.218728_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218728_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218728_bib6","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218728_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/JTO.0b013e31816de28f","article-title":"Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2026.218728_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.canlet.2026.218728_bib9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/JTO.0000000000000160","article-title":"A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015)","volume":"9","author":"Mok","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2026.218728_bib10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1158\/1078-0432.CCR-07-1154","article-title":"Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study","volume":"14","author":"Dowlati","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218728_bib11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218728_bib12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: Tumor-intrinsic and -Extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218728_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4049\/jimmunol.1701269","article-title":"Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity","volume":"200","author":"Engelhard","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218728_bib14","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: an intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218728_bib15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218728_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s13402-025-01052-x","article-title":"Spatial distribution of tertiary lymphoid structures in the molecular and clinical context of non-small cell lung cancer","author":"Elfving","year":"2025","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.canlet.2026.218728_bib17","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.jtho.2022.04.015","article-title":"Bevacizumab plus atezolizumab in pretreated progressive and metastatic NSCLC","volume":"17","author":"Zhao","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2026.218728_bib18","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218728_bib19","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218728_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101077","article-title":"Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer","volume":"59","author":"Lin","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2026.218728_bib21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218728_bib22","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218728_bib23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218728_bib24","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2025.05.016","article-title":"Lenvatinib plus pembrolizumab, pemetrexed, and a platinum as first-line therapy for metastatic nonsquamous NSCLC: phase 3 LEAP-006 study","volume":"20","author":"Herbst","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2026.218728_bib25","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jtho.2025.06.031","article-title":"Where do we Go with the combination of immune checkpoint inhibitors with anti-angiogenesis in advanced NSCLC?","volume":"20","author":"Wang","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2026.218728_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF01064374","article-title":"Laboratory measurement of thrombin Activity--What every clinician scientist needs to know","volume":"2","author":"Merlini","year":"1995","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.canlet.2026.218728_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86837","article-title":"Profiling cancer testis antigens in non-small-cell lung cancer","volume":"1","author":"Djureinovic","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218728_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.phrs.2016.11.022","article-title":"Modulation of VEGF receptor 2 signaling by protein phosphatases","volume":"115","author":"Corti","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2026.218728_bib29","article-title":"Uncovering a distinct gene signature in endothelial cells associated with contrast enhancement in glioblastoma","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218728_bib30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cels.2016.08.001","article-title":"Analysis of body-wide unfractionated tissue data to identify a core human endothelial transcriptome","volume":"3","author":"Butler","year":"2016","journal-title":"Cell Syst."},{"key":"10.1016\/j.canlet.2026.218728_bib31","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/ncomms2683","article-title":"VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation","volume":"4","author":"Hayashi","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218728_bib32","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2967\/jnumed.112.115014","article-title":"PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients","volume":"54","author":"Bollineni","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2026.218728_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1152\/physiol.00026.2020","article-title":"Vascular endothelial protein tyrosine phosphatase regulates endothelial function","volume":"36","author":"Vestweber","year":"2021","journal-title":"Physiology"},{"key":"10.1016\/j.canlet.2026.218728_bib34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nm1091","article-title":"Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity","volume":"10","author":"Moyron-Quiroz","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218728_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2353\/ajpath.2010.090446","article-title":"Initiation of acquired immunity in the lungs of mice lacking lymph nodes after infection with aerosolized Mycobacterium tuberculosis","volume":"176","author":"Kashino","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2026.218728_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022681","article-title":"Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"6","author":"Lima","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218728_bib39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2213-2600(21)00166-1","article-title":"Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Kawashima","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.canlet.2026.218728_bib40","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218728_bib41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1515\/med-2020-0192","article-title":"Bevacizumab for non-small cell lung cancer patients with brain metastasis: a meta-analysis","volume":"15","author":"Liang","year":"2020","journal-title":"Open Med."},{"key":"10.1016\/j.canlet.2026.218728_bib42","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/PAI.0000000000000235","article-title":"Various antibody clones of napsin A, thyroid transcription factor 1, and p40 and comparisons with cytokeratin 5 and p63 in histopathologic diagnostics of non-small cell lung carcinoma","volume":"24","author":"Tran","year":"2016","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.canlet.2026.218728_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001469","article-title":"Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer","volume":"9","author":"Marwitz","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218728_bib44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","article-title":"Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma","volume":"79","author":"O'Reilly","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218728_bib45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-0716-2059-5_10","article-title":"Imaging blood vessels and lymphatics in mouse trachea wholemounts","volume":"2441","author":"Baluk","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218728_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.canlet.2026.218728_bib47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s42255-019-0045-8","article-title":"Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy","volume":"1","author":"Ye","year":"2019","journal-title":"Nat. Metab."},{"key":"10.1016\/j.canlet.2026.218728_bib48","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/srep00765","article-title":"12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?","volume":"2","author":"Messina","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218728_bib49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.5026","article-title":"Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients","volume":"244","author":"Mezheyeuski","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2026.218728_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2023.02.012","article-title":"Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer","volume":"185","author":"Backman","year":"2023","journal-title":"Eur. J. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:46:13Z","timestamp":1788482773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"alternative-id":["S0304383526004921"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218728","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vascular leakage in non-small cell lung cancer is associated with immune evasion and poor response to immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218728"}}